Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

Vericel Corporation logoVericel Corporation

VCEL · Nasdaq · USD · Market cap $3.0B · 398 employees

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe…

PASS · Titan Ethical · score 70.0
57.52 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price57.52 USD at the 20 Nov 2026 close
  • Our value readOvervalued vs our fair value, as of 20 Nov 2026
  • Our regime readMarkup, as of 16 Nov 2026
  • Ethical screenPasses, score 70.0 out of 100
  • OptionsOpen interest leans heavily to calls (put/call 0.06)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $42.36 to $48.72, base estimate $42.36 (screen dated 2026-11-20).

Current read
Markup ?
Overvalued · screened 2026-11-20
  • Trend Markup
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.06, read 2026-11-20
  • Ethical passes the values gate
Price57.52 USD
Fair value42.36
Ethical score70.0/100
Value readOvervaluedas of 20 Nov 2026
Our investment reviews on this name
2026-11-12Read Markup59.45-3.2% to today Accumulation gives way to Markup after a 31% rise in 7 days
2026-11-05Read Accumulation45.48+26.5% to today ✓Markdown gives way to Accumulation after an 11% rise in 1 days
2026-11-04Read Markdown41.09+40.0% to today Accumulation gives way to Markdown first Markdown read since September
2026-10-02Read Accumulation39.55+45.4% to today ✓Markdown gives way to Accumulation after a 12% slide in 7 weeks

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Vericel Corporation holds its Markup at $57.52. The statistical read favours the sellers, held for 10 days.

As held on the ledger · 2026-11-20
PhaseMarkup
Quantitative stateThe statistical read favours the sellers, held for 10 days
Price at the screen$57.52
Valuation90.44 trailing · 61.44 forward price to earnings
Values screenPASS · score 70.0
Beta1.06
The Workings

Five Screens: VCEL's Results

PASS. All five recorded results clear their limits.

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 19.75% Below 33% Pass
Interest-bearing cash 12.58% Below 33% Pass
Receivables 37.86% Below 49% Pass
Revenue purity 2.54% Below 5% Pass

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Clears, in Plain English

PASS · Titan Ethical

Vericel clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 20%, inside the ~33% line, and interest is about 3% of its income, under the ~5% line, so it passes.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when VCEL's ethical verdict changes

Today VCEL passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Overvalued to fair value, as of 20 Nov 2026: it trades above our $42.36 fair value estimate, 26.50% revenue growth.

Method.

42.36Conservative42.36Base case48.72Growth case 57.52Price

USD, 2026-11-20 screen. The price runs 35.8% over base.

The Street's Range
60.00Street low 64.00Street average 75.00Street high 57.52Price

Street: 7 covering, consensus Strong Buy. Average target +11%.

Chart
The Business, in Plain Words

Cell Patches Priced Well Beyond Their Reach

Picture a surgeon grafting living cells onto a burned patient or a torn cartilage in an athlete. Vericel supplies those therapies in North America and has lifted revenue 30 percent. Yet the business still clears only a 7 percent profit margin and a matching 7 percent return on equity, leaving little evidence of durable advantage.

We pass. At 54.7 times forward earnings the shares sit 21 percent above our fair value, and the market's strong buy chorus has already baked in flawless execution. An unknown moat in a field where competitors and regulators can shift quickly makes that premium look fragile rather than compelling.

Growth is real and the ethical screen clears, but the numbers show a company that must deliver far more than its current returns to justify today's price. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E61.4xexpensive even after accounting for its growth
Trailing P/E90.4xexpensive: the price assumes strong growth ahead
EPS, trailing0.64
EPS, forward0.94
Revenue growth+26.5%strong top-line growth
Profit margin10.3%thin but positive margins
Return on equity9.4%a modest return on shareholder capital
FCF yield1.69%
Debt to equity0.24minimal debt: a conservative balance sheet
Current ratio5.13comfortably covers its short-term bills
Beta1.06moves a little more than the market
Short interest, float0.14%
52-week range28.95 - 59.75
Market cap$3.0B
Employees398

VCEL-specific watchpoints · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Markup $58.26 -0.7% Entry 20
2026-11-19 Markup $58.65 -1.3% Entry 19
2026-11-12 Markup · changed $59.45 +30.7% Entry 18

The framework has shifted from accumulation to markup since the last review.

2026-11-05 Accumulation · changed $45.48 +10.7% Entry 17

The framework has shifted from markdown to accumulation since the last review.

2026-11-04 Markdown · changed $41.09 +1.4% Entry 16

The framework has shifted from accumulation to markdown since the last review.

2026-11-03 Accumulation $40.51 +0.6% Entry 15
2026-11-02 Accumulation $40.26 +0.0% Entry 14
2026-11-01 Accumulation $40.26 +0.0% Entry 13
2026-10-31 Accumulation $40.26 -6.2% Entry 12
2026-10-30 Accumulation $42.91 +4.4% Entry 11

Earnings landed in this window. Ethical screening: PASS.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on VCEL

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in VCEL's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $32.92 +13.6% · $1,136 +13.6%
2 months $33.70 +10.9% · $1,109 +10.9%
3 months $32.11 +16.4% · $1,164 +16.4%
6 months $37.39 0.0% · $1,000 0.0%
1 year $45.70 -18.2% · $818 -18.2%
2 years $43.53 -14.1% · $859 -14.1%
3 years $34.96 +6.9% · $1,069 +6.9%
5 years $57.58 -35.1% · $649 -35.1%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever VCEL does next, these words stay.

Vericel Corporation · VCEL · Markup · $57.52
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.